{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:54:09Z","timestamp":1791910449127,"version":"4.3.4"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360586"],"award-info":[{"award-number":["82360586"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302169"],"award-info":[{"award-number":["81302169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81360366"],"award-info":[{"award-number":["81360366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Province Science and Technology Foundation","doi-asserted-by":"publisher","award":["[2020]1Z064"],"award-info":[{"award-number":["[2020]1Z064"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Province Science and Technology Foundation","doi-asserted-by":"publisher","award":["[2019]1198"],"award-info":[{"award-number":["[2019]1198"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118270","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:03:45Z","timestamp":1784588625000},"page":"118270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Antibody-drug conjugates in colorectal cancer: advances, challenges, and prospectives"],"prefix":"10.1016","volume":"253","author":[{"given":"Lili","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0010","first-page":"57","article-title":"Current status of global colorectal cancer prevalence, prevention and control","volume":"46","author":"Guo","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"10449","key":"10.1016\/j.bcp.2026.118270_b0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13046-021-02229-6","article-title":"ROS\/PI3K\/Akt and Wnt\/\u03b2-catenin signalings activate HIF-1\u03b1-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer","volume":"41","author":"Dong","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0035","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118270_b0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"20","key":"10.1016\/j.bcp.2026.118270_b0045","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a Novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118270_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108116","article-title":"Dual-targeting inhibitors involving tubulin for the treatment of cancer","volume":"156","author":"Yakkala","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40265-025-02185-x","article-title":"Datopotamab deruxtecan: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"issue":"25","key":"10.1016\/j.bcp.2026.118270_b0065","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase ii LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118270_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112260","article-title":"Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy","volume":"144","author":"Al-Mansoori","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118270_b0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.actbio.2019.01.011","article-title":"Oriented immobilization to nanoparticles enhanced the therapeutic efficacy of antibody drugs","volume":"86","author":"Iijima","year":"2019","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2478\/s11658-013-0094-z","article-title":"Tubulin-interactive stilbene derivatives as anticancer agents","volume":"18","author":"Mikstacka","year":"2013","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0090","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/mp500781a","article-title":"Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985","volume":"12","author":"Elgersma","year":"2015","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0095","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-21-0851","article-title":"ABBV-011, a novel, calicheamicin-based antibody-drug conjugate, targets SEZ6 to eradicate small cell lung cancer tumors","volume":"21","author":"Wiedemeyer","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1878-0261.12166","article-title":"A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30(+) lymphomas","volume":"12","author":"Wang","year":"2018","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0105","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41375-025-02642-2","article-title":"KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML","volume":"39","author":"Zou","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1021\/acs.bioconjchem.6b00530","article-title":"Investigation of hydrophilic auristatin derivatives for use in antibody drug conjugates","volume":"28","author":"Mendelsohn","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","article-title":"Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond","volume":"6","author":"Garc\u00eda-Alonso","year":"2020","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"16","key":"10.1016\/j.bcp.2026.118270_b0125","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0130","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0135","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118270_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1230395","article-title":"Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118270_b0145","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","article-title":"Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2026.118270_b0150","article-title":"Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer","volume":"306","author":"Ding","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.118270_b0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0160","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer","volume":"13","author":"Weng","year":"2023","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bcp.2026.118270_b0165","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118270_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0175","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/mco2.671","article-title":"Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm (2020)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"issue":"27","key":"10.1016\/j.bcp.2026.118270_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202302805","article-title":"Self-assembled L-DNA linkers for rapid construction of multi-specific antibody-drug conjugates library","volume":"62","author":"Zhou","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2026.118270_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114641","article-title":"C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma","volume":"190","author":"Yang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118270_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102922","article-title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","volume":"135","author":"G\u00e9raud","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.118270_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124211","article-title":"Antibody-drug conjugates: a promising breakthrough in cancer therapy","volume":"659","author":"Parit","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0205","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"issue":"20","key":"10.1016\/j.bcp.2026.118270_b0210","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118270_b0215","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jpha.2020.05.008","article-title":"Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates","volume":"10","author":"Zhu","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.bcp.2026.118270_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.113027","article-title":"Hydrophobic interaction chromatography (HIC) method development and characterization of resolved drug-load variants in site-specifically conjugated pyrrolobenzodiazepine dimer-based antibody drug conjugates (PBD-ADCs)","volume":"179","author":"Janaratne","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bcp.2026.118270_b0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jpba.2017.06.022","article-title":"Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates","volume":"147","author":"Bob\u00e1ly","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bcp.2026.118270_b0235","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.chroma.2018.12.020","article-title":"Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates?","volume":"1586","author":"D'Atri","year":"2019","journal-title":"J. Chromatogr. A"},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0240","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","article-title":"Analytical methods for physicochemical characterization of antibody drug conjugates","volume":"3","author":"Wakankar","year":"2011","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0245","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14789450.2019.1578215","article-title":"Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future","volume":"16","author":"Beck","year":"2019","journal-title":"Expert Rev. Proteomics"},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0250","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of payload hydrophobicity on the stability of antibody-drug conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0255","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.xphs.2019.08.006","article-title":"Alteration of physicochemical properties for antibody-drug conjugates and their impact on stability","volume":"109","author":"Buecheler","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0260","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4161\/mabs.19449","article-title":"Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates","volume":"4","author":"Acchione","year":"2012","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0265","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1038\/s41598-025-92697-z","article-title":"Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy","volume":"15","author":"Chang","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of antibody-drug conjugates in cancer cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.118270_b0275","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1016\/j.apsb.2021.05.024","article-title":"Target-responsive subcellular catabolism analysis for early-stage antibody-drug conjugates screening and assessment","volume":"11","author":"Sang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0280","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0285","article-title":"Improved translation of stability for conjugated antibodies using an in vitro whole blood assay","volume":"12","author":"Fourie-O'Donohue","year":"2020","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0290","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid\u2013valine\u2013citrulline linkers ensure stability and efficacy of antibody\u2013drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0295","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1021\/ml100039h","article-title":"Expanded utility of the \u03b2-glucuronide linker: ADCs that deliver phenolic cytotoxic agents","volume":"1","author":"Jeffrey","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bcp.2026.118270_b0300","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118270_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102826","article-title":"Targeting HER2 in solid tumors: unveiling the structure and novel epitopes","volume":"130","author":"Liu","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0310","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/s41467-021-23053-8","article-title":"Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer","volume":"12","author":"Shi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118270_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116101","article-title":"HER2 targeted therapy in colorectal cancer: current landscape and future directions","volume":"223","author":"Chen","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118270_b0320","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0325","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118270_b0330","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.bcp.2026.118270_b0335","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2026.118270_b0340","doi-asserted-by":"crossref","unstructured":"Xu, H., J. Peng, H. Wu, L. Yang, et al, Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation\/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study. Journal of Clinical Oncology, 2024. 42(16_suppl): p. e15003-e15003, Doi: 10.1200\/JCO.2024.42. 16_suppl.e15003.","DOI":"10.1200\/JCO.2024.42.16_suppl.e15003"},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues","volume":"9","author":"Hammarstr\u00f6m","year":"1999","journal-title":"Semin. Cancer Biol."},{"issue":"3\u20134","key":"10.1016\/j.bcp.2026.118270_b0350","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev."},{"issue":"29","key":"10.1016\/j.bcp.2026.118270_b0355","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II trial of labetuzumab govitecan (Anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118270_b0360","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1021\/acsmedchemlett.4c00168","article-title":"Novel exatecan-derived topoisomerase-1 inhibitors for treating cancer","volume":"15","author":"Sabnis","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0365","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccr.2004.06.013","article-title":"The Sema domain of Met is necessary for receptor dimerization and activation","volume":"6","author":"Kong-Beltran","year":"2004","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0370","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jcb.10358","article-title":"HGF\/SF-met signaling in the control of branching morphogenesis and invasion","volume":"88","author":"Zhang","year":"2003","journal-title":"J. Cell. Biochem."},{"issue":"16_suppl","key":"10.1016\/j.bcp.2026.118270_b0375","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1200\/JCO.2024.42.16_suppl.3515","article-title":"First-in-human study of ABBV-400, a novel c-Met\u2013targeting antibody-drug conjugate, in advanced solid tumors: results in colorectal cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118270_b0380","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"19","key":"10.1016\/j.bcp.2026.118270_b0385","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910260","article-title":"Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?","volume":"22","author":"Stefani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0390","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0395","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41598-025-85856-9","article-title":"EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells","volume":"15","author":"Jafary","year":"2025","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.bcp.2026.118270_b0400","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1158\/0008-5472.CAN-24-2266","article-title":"An anti-EGFR antibody-drug radioconjugate labeled with actinium-225 elicits durable antitumor responses in KRAS- and BRAF-mutant colorectal cancer","volume":"85","author":"Tikum","year":"2025","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0405","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003053","article-title":"Structure and biochemistry of cadherins and catenins","volume":"1","author":"Shapiro","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"20","key":"10.1016\/j.bcp.2026.118270_b0410","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26209838","article-title":"The role of cadherin 17 (CDH17) in cancer progression via Wnt\/\u03b2-catenin signalling pathway: a systematic review and meta-analysis","volume":"26","author":"Tha Shrestha","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0415","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1535-7163.MCT-20-0253","article-title":"Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist","volume":"20","author":"Garc\u00eda-Mart\u00ednez","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0420","article-title":"Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0425","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41420-025-02652-0","article-title":"Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer","volume":"11","author":"Zhang","year":"2025","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0430","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s42003-021-02189-9","article-title":"Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern","volume":"4","author":"Tabari\u00e8s","year":"2021","journal-title":"Commun. Biol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118270_b0435","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/MCB.00299-12","article-title":"Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes","volume":"32","author":"Tabari\u00e8s","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118270_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101402","article-title":"Overexpression of CEACAM6 activates Src-FAK signaling and inhibits anoikis, through homophilic interactions in lung adenocarcinomas","volume":"20","author":"Kim","year":"2022","journal-title":"Transl. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0445","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5615","article-title":"The emerging roles of CEACAM6 in human cancer (Review)","volume":"64","author":"Wu","year":"2024","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0450","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1158\/1535-7163.MCT-24-0444","article-title":"Broad-spectrum efficacy of CEACAM6-targeted antibody-drug conjugate with BET protein degrader in colorectal, lung, and breast cancer mouse models","volume":"24","author":"Kogai","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bcp.2026.118270_b0455","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-05-1961","article-title":"Clinical significance of TROP2 expression in colorectal cancer","volume":"12","author":"Ohmachi","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"60","key":"10.1016\/j.bcp.2026.118270_b0460","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.18632\/oncotarget.27299","article-title":"Correction: TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K\/AKT pathway and inducing EMT","volume":"10","author":"Li","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0465","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"issue":"Pt 4","key":"10.1016\/j.bcp.2026.118270_b0470","article-title":"Selection of trophoblast cell surface antigen 2-targeted aptamer for the development of cytotoxic aptamer-drug conjugate","volume":"279","author":"Li","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118270_b0475","doi-asserted-by":"crossref","first-page":"14772","DOI":"10.1074\/jbc.M309678200","article-title":"Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80\/gp140\/CUB domain-containing protein 1 in epithelia","volume":"279","author":"Brown","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118270_b0480","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1158\/0008-5472.CAN-20-2978","article-title":"The CDCP1 signaling hub: a target for cancer detection and therapeutic intervention","volume":"81","author":"Khan","year":"2021","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.bcp.2026.118270_b0485","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.7150\/thno.78171","article-title":"CUB domain-containing protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy","volume":"12","author":"Khan","year":"2022","journal-title":"Theranostics"},{"issue":"7360","key":"10.1016\/j.bcp.2026.118270_b0490","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature10337","article-title":"Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling","volume":"476","author":"de Lau","year":"2011","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.bcp.2026.118270_b0495","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194243","article-title":"Cancer-associated fibroblasts enhance colorectal cancer lymphatic metastasis via CLEC11A\/LGR5-mediated WNT pathway activation","volume":"135","author":"Zhang","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bcp.2026.118270_b0500","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/s44321-024-00121-2","article-title":"Novel immunotherapeutics against LGR5 to target multiple cancer types","volume":"16","author":"Chen","year":"2024","journal-title":"EMBO Mol. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118270_b0505","article-title":"Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models","volume":"6","author":"High","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bcp.2026.118270_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103012","article-title":"Combining antibody-drug conjugates with immune checkpoint inhibitors: a new paradigm for breast cancer therapy","volume":"140","author":"Xu","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0515","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011881","article-title":"Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48","volume":"13","author":"Xiao","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0520","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.62347\/GMRV6636","article-title":"HER2-positive, RAS-mutant, MSS colorectal cancer: a rare subtype report and novel insights into immunotherapy and ADC combinations","volume":"15","author":"Kong","year":"2025","journal-title":"Am. J. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0525","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","article-title":"A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway","volume":"14","author":"Wu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0530","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41419-024-06572-2","article-title":"Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0535","article-title":"Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0540","first-page":"105","article-title":"Tumor heterogeneity: causes and consequences","volume":"1805","author":"Marusyk","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0545","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jnci\/djab106","article-title":"Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis","volume":"114","author":"Ten Hoorn","year":"2022","journal-title":"J. Natl Cancer Inst."},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0550","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0555","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40265-025-02253-2","article-title":"Targeting HER2 in metastatic colorectal cancer: current therapies, biomarker refinement, and emerging strategies","volume":"86","author":"Vaghi","year":"2026","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0560","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0565","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/cas.14983","article-title":"Barriers to antibody therapy in solid tumors, and their solutions","volume":"112","author":"Matsumura","year":"2021","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0570","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","article-title":"Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models","volume":"80","author":"Nessler","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0575","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10020-023-00665-y","article-title":"Cancer-associated fibroblasts and its derived exosomes: a new perspective for reshaping the tumor microenvironment","volume":"29","author":"Peng","year":"2023","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.118270_b0580","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1007\/s00262-023-03520-5","article-title":"PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies","volume":"72","author":"Lin","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2026.118270_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298524","article-title":"The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer","volume":"14","author":"Ding","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0590","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf158","article-title":"Investigating incidence of RAS\/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis","volume":"30","author":"Cheng","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bcp.2026.118270_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117363","article-title":"Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer","volume":"179","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0600","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118270_b0605","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"11","key":"10.1016\/j.bcp.2026.118270_b0610","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118270_b0615","article-title":"Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters","author":"Roth","year":"2025","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.bcp.2026.118270_b0620","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051245","article-title":"ML210 antagonizes ABCB1- not ABCG2-mediated multidrug resistance in colorectal cancer","volume":"13","author":"Li","year":"2025","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0625","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","article-title":"Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0630","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","article-title":"EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd","volume":"82","author":"Haikala","year":"2022","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0635","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/cas.70319","article-title":"Therapeutic strategies to overcome payload resistance of trastuzumab deruxtecan in HER2-positive cancers","volume":"117","author":"Murase","year":"2026","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0640","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087233","article-title":"Resistance to TOP-1 inhibitors: good old drugs still can surprise us","volume":"24","author":"Kumar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0645","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: a Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118270_b0650","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0655","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody-drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0660","doi-asserted-by":"crossref","DOI":"10.3390\/molecules31071180","article-title":"Antibody-drug conjugates (ADCs): a review of structural design, technological evolution, and future perspectives","volume":"31","author":"Wu","year":"2026","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.bcp.2026.118270_b0665","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1124\/dmd.115.064253","article-title":"Intracellular catabolism of an antibody drug conjugate with a noncleavable linker","volume":"43","author":"Rock","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0670","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"21","key":"10.1016\/j.bcp.2026.118270_b0675","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215472","article-title":"Phase I dose-escalation trial of an innovative chemotherapy regimen combining a fractionated dose of irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) in chemorefractory metastatic colorectal cancer","volume":"13","author":"Bellio","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0680","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bcp.2026.118270_b0685","doi-asserted-by":"crossref","first-page":"761","DOI":"10.5306\/wjco.v11.i10.761","article-title":"Colorectal liver metastases: current management and future perspectives","volume":"11","author":"Martin","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bcp.2026.118270_b0690","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.clbc.2024.04.003","article-title":"Gastrointestinal toxicity of antibody drug conjugates (ADCs) in metastatic breast cancer: a pooled analysis","volume":"24","author":"Pedersini","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bcp.2026.118270_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102865","article-title":"Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: a systematic review and network meta-analysis","volume":"132","author":"Schettini","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.118270_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118270_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107778","article-title":"Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates","volume":"26","author":"Fu","year":"2023","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0710","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2026.118270_b0715","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060655","article-title":"Development of photoremovable linkers as a novel strategy to improve the pharmacokinetics of drug conjugates and their potential application in antibody-drug conjugates for cancer therapy","volume":"15","author":"Johan","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2026.118270_b0720","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10388","article-title":"Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect","volume":"7","author":"Takahashi","year":"2022","journal-title":"Bioeng. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0725","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41467-018-03880-y","article-title":"Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice","volume":"9","author":"Rossin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118270_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106982","article-title":"Click chemistry in the synthesis of antibody-drug conjugates","volume":"143","author":"Dudchak","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"23","key":"10.1016\/j.bcp.2026.118270_b0735","doi-asserted-by":"crossref","first-page":"24968","DOI":"10.1021\/acs.jmedchem.5c01908","article-title":"Dissecting the efficacy and immunogenicity of TLR7 agonist-antibody conjugates through the lens of fc effector function, conjugation strategies, and linker cleavability","volume":"68","author":"Fang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0740","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1038\/s41467-024-49932-4","article-title":"Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses","volume":"15","author":"Malli Cetinbas","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118270_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?","volume":"203","author":"Fu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118270_b0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118270_b0755","doi-asserted-by":"crossref","unstructured":"Palacino, J., C. Bai, Y. Yi, A. Skaletskaya, et al, Abstract 3933: ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer. Cancer Research, 2022. 82(12_Supplement): p. 3933-3933, Doi: 10.1158\/1538-7445. AM2022-3933.","DOI":"10.1158\/1538-7445.AM2022-3933"},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0760","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0765","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","article-title":"A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs","volume":"43","author":"Huang","year":"2025","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118270_b0770","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.bcp.2026.118270_b0775","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","article-title":"A dual-payload antibody-drug conjugate targeting CD276\/B7-H3 elicits cytotoxicity and immune activation in triple-negative breast cancer","volume":"84","author":"Zhou","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118270_b0780","doi-asserted-by":"crossref","unstructured":"Zhao, Y., P. Ren, M. Guan, J. Tang, et al, Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model. Cancer Research, 2025. 85(8_Supplement_1): p. 1585-1585, Doi: 10.1158\/1538-7445. AM2025-1585.","DOI":"10.1158\/1538-7445.AM2025-1585"},{"issue":"4","key":"10.1016\/j.bcp.2026.118270_b0785","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(25)00733-8","article-title":"Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1\/2 trial","volume":"27","author":"Johnson","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2026.118270_b0790","doi-asserted-by":"crossref","unstructured":"Ott, J.M., V. Gassenmaier, M. Bitzer, C.M. Sch\u00fcrch, et al, B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment. Pathology and Oncology Research, 2025. Volume 31 - 2025, Doi: 10.3389\/pore.2025.1612186.","DOI":"10.3389\/pore.2025.1612186"},{"issue":"12","key":"10.1016\/j.bcp.2026.118270_b0795","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118270_b0800","first-page":"1391","article-title":"Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development","volume":"128","author":"Moretto","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118270_b0805","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/23808993.2021.1876518","article-title":"GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer","volume":"6","author":"Lisby","year":"2021","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"issue":"8","key":"10.1016\/j.bcp.2026.118270_b0810","first-page":"1592","article-title":"An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer","volume":"128","author":"Jacob","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.118270_b0815","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1158\/1535-7163.MCT-22-0817","article-title":"SGN-B6A: a new vedotin antibody-drug conjugate directed to integrin beta-6 for multiple carcinoma indications","volume":"22","author":"Lyon","year":"2023","journal-title":"Mol. Cancer Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600609X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600609X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:28:35Z","timestamp":1791908915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600609X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":163,"alternative-id":["S000629522600609X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118270","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates in colorectal cancer: advances, challenges, and prospectives","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118270"}}